Jump Financial LLC Sells 6,751 Shares of Delcath Systems, Inc. $DCTH

Jump Financial LLC decreased its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 19.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,013 shares of the company’s stock after selling 6,751 shares during the period. Jump Financial LLC owned 0.08% of Delcath Systems worth $357,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Delcath Systems by 13.8% during the 1st quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company’s stock valued at $17,746,000 after buying an additional 169,260 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in Delcath Systems during the 4th quarter valued at approximately $9,644,000. Invesco Ltd. purchased a new stake in Delcath Systems during the 1st quarter valued at approximately $5,084,000. Millennium Management LLC grew its holdings in Delcath Systems by 53.4% during the 4th quarter. Millennium Management LLC now owns 314,675 shares of the company’s stock valued at $3,789,000 after buying an additional 109,568 shares in the last quarter. Finally, Informed Momentum Co LLC grew its holdings in Delcath Systems by 218.7% during the 1st quarter. Informed Momentum Co LLC now owns 208,604 shares of the company’s stock valued at $2,656,000 after buying an additional 143,157 shares in the last quarter. 61.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DCTH has been the subject of a number of research analyst reports. HC Wainwright increased their price objective on shares of Delcath Systems from $29.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Stephens reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Delcath Systems in a report on Monday, June 23rd. Finally, Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Delcath Systems presently has an average rating of “Buy” and a consensus price target of $24.50.

Delcath Systems Stock Down 1.1%

Shares of DCTH opened at $10.90 on Wednesday. The company has a market cap of $381.28 million, a PE ratio of 218.00 and a beta of 0.85. The business has a fifty day moving average of $11.41 and a 200 day moving average of $12.98. Delcath Systems, Inc. has a 52-week low of $8.08 and a 52-week high of $18.23.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. The company had revenue of $24.16 million during the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. As a group, research analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.